Global Market Study on Cancer Supportive Care Products: High Consumption of Erythropoietin Stimulating Agents to Drive the Market in Forecast Period


  • Published On : Dec-2015 |
  • Pages : 212 Pages |
  • Format :

This Persistence Market Research (PMR) report examines the global cancer supportive care products market for the period 2015 - 2021. The primary objective of the report is to offer updates and information related to market opportunities in the global cancer supportive care products market.

The global cancer supportive care products market report deals with cancer supportive care drugs, which can be defined as products or drugs that are mainly used for treatment of adverse effects associated with cancer therapy as well as for the treatment of the symptoms and signs of cancer drugs, such as chemotherapy-induced nausea and vomiting, chemotherapy induced neutropenia, chemotherapy-induced anemia, hair loss, etc. On the basis of drug classes, the market has been segmented into non-steroidal anti-inflammatory drugs, anti-infective, anti-emetics, monoclonal antibodies, erythropoietin stimulating agents, opioid analgesics, bisphosphonates, and granulocyte colony stimulating factors. The global cancer supportive care products market is expected to expand at a CAGR of 4.3% over the forecast period (2015–2021) to account for US$ 31,700 Mn by 2021.

To understand and assess the opportunities in this market, the report is categorically split into four sections, namely market analysis by drug class, disease indication, distribution channel, and region. The report analyzes the global compounding pharmacies market in terms of market value (US$ Mn).

The report starts with an overview of the global cancer supportive care products market and its usage in the treatment of various chemotherapy-associated side-effects across the globe. In the same section, PMR covers the global cancer supportive care products market performance in terms of revenue. This section includes PMR’s analysis of key trends, drivers, and restraints from supply and demand perspectives.

The next section of the report analyzes the market on the basis of drug class segments and presents the forecast in terms of value for all the years till 2021.

Cancer supportive care products market: Drug classes covered in the report are as follows:

  • Non-steroidal anti-inflammatory drugs
  • Anti-infective
  • Anti-emetics
  • Monoclonal antibodies
  • Erythropoietin stimulating agents
  • Opioid analgesics
  • Bisphosphonates
  • Granulocyte colony stimulating factors

The next section of the report analyzes the market on the basis of the disease indication segments and presents the forecast in terms of value for the following six years.

Cancer supportive care products market: Disease indication segments covered in the report are as follows

  • Lung cancer
  • Breast cancer
  • Prostate cancer
  • Liver cancer
  • Bladder cancer
  • Leukemia
  • Ovarian cancer
  • Melanoma
  • Others

Post disease indications, the following section of the report analyzes the market on the basis of distribution channels for the forecast period, in terms of value.

Cancer supportive care products market: Distribution channels covered in the report are as follows

  • Hospital pharmacies
  • Retail pharmacies
  • Compounding pharmacies

The section that follows analyzes the market on the basis of regions in terms of value for the forecast period.

Cancer supportive care products market: Regions covered in the report are as follows

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East & Africa 

To arrive at the market size, the report considers the market value of the global cancer supportive care products across the aforementioned geographies. The forecast presented in the report assesses the total revenue generated in the global cancer supportive care product market. When developing the market forecast, the starting point involves sizing the current market, which forms the basis for the forecast of how the market is anticipated to take shape in the near future. For this, PMR referred to several subject matter experts in the cancer supportive care products domain. Given the characteristics of the market, we triangulated the outcome based on different analysis based on the supply side, demand side, and dynamics of the market, such as regulations and GMP guidelines for cancer supportive care products. In this report, quantification of data has been conducted along with the provision of quality insights collected directly from the market through discussion with pharmacists, suppliers, physicians, and subject matter experts. This is how the market analysis for the forecast period is carried out.

We have also taken into consideration the year-on-year growth of the global cancer supportive care products market, based on regional growth analysis, to understand the predictability of the market and to identify the right opportunities in it.

As previously highlighted, the market for global cancer supportive care products is split into various segments on the basis of drug classes, disease indications, distribution channels, and regions. All these segments have been analyzed in terms of Basis Point Share (BPS) to understand the individual segments’ relative contribution to market growth. This detailed level of information is important for identification of various key trends in the global cancer supportive care products market.

Another key feature of this report is the analysis of the global cancer supportive care products market, by region, which is further segmented on the basis of countries and revenue forecast in terms of absolute dollar opportunity. Regional trends have been introspected, identified, and applied while forecasting the growth rates of the market. Additionally, the absolute dollar opportunity provided in the report is critical in assessing the level of opportunity that a provider can look to achieve from a sales perspective in the global cancer supportive care products market. 

In this report, PMR has also developed the market attractiveness index for all four segments, namely drug classes, disease indication, distribution channels, and regional segments. This index is intended to help in identifying the real opportunities in the market.

In the final section of the report, the global cancer supportive care products market landscape is included to provide report audiences with a dashboard view, based on categories of providers in the global cancer supportive care product portfolio; their key developments and strategies have also been included wherever possible. 

Progress in cancer treatment procedures, with it, has brought challenges that go beyond cure. Toxicity and morbidity are among the biggest hurdles that a cancer patient has to face while undergoing chemotherapy or radiation therapy. Host of path-breaking technological advancements have been made in the science of supportive care for treating chemotherapy induced side effects, such as bone metastasis, cancer pain, oral mucositis, chemotherapy induced neutropenia, chemotherapy induced nausea and vomiting, chemotherapy induced anemia, and various signs and symptoms associated with it. Cancer supportive care products or drugs are used in the treatment of side effects as well as various signs and symptoms associated with chemotherapy. Drugs used for the treatment of chemotherapy induced side effects belong to one of the drug classes mentioned below: non-steroidal anti-inflammatory drugs, anti-infective, anti-emetics, monoclonal antibodies, erythropoietin stimulating agents, opioid analgesics, bisphosphonates, and granulocyte colony stimulating factors.

Globally, cancer supportive care products market is estimated to account for a market value of US$ 24,620 Mn by the end of 2015, and it is projected to witness stable growth across all global regions, due to rising incidences of cancer, leading to increasing demand for effective cancer supportive care products.        

The primary growth driver for the cancer supportive care products market are the rising incidences of various forms of cancers worldwide. According to Globocan 2012, there were 14.1 Mn cancer cases estimated worldwide in 2012. Lung cancer was seen to be the most common cancer worldwide among men, accounting for nearly 17% of the total number of new cases diagnosed in 2012. Furthermore, greater effectiveness of anti-cancer drugs, such as anti-emetics drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), opioid analgesics drugs, etc., has been driving the growth of the global cancer supportive care products market over the last few years. These drugs help prevent side-effects of cancer treatment on the patient, due to which adoption rate of these cancer supportive care drugs has been on the rise.

Manufacturers of cancer supportive care products are more focused on innovation and development of new drugs to maintain a competitive advantage in the market. Many manufacturers have introduced various new drugs for the treatment of cancer and for therapeutic approaches, including preventive vaccines and cancer supportive care products. Over the last two years, 21 new molecular entities have been launched. These new medicines have increased the possibility of treating cancer, leading to more combination therapies and additional lines of therapy.

The rise in overall healthcare expenditure is also expected to contribute to the overall growth of the cancer supportive care products market in the coming years. Healthcare expenditure in the U.S. is projected to grow at an average annual rate of 5.8% during the forecast period. By 2022, healthcare spending in the country is projected to account for around 19.9% of its GDP. This is expected to boost the overall healthcare spending by patients suffering from cancer in the country.

Globally, the market in North America is expected to expand at the strongest CAGR in terms of value throughout the forecast period.  The U.S. market in North America is estimated to witness a single digit growth during the forecast period. Higher healthcare spending and rising number of initiatives by the government to improve access to various drugs and increase adherence, along with direct-to-consumer marketing in the U.S., are factors that are expected to continue to further drive demand for  the cancer supportive care products and, thus, lead to standardization of the market in the region. Currently, erythropoietin stimulating agents segment dominates the region in terms of drug class popularity. However, cost issues and lack of reimbursement policies are expected to slightly hamper the growth of the market in North America during the forecast period.

Europe is the second-most lucrative destination for cancer supportive care products currently. Absence of post-treatment patient care in Eastern Europe is expected to affect the overall market for supportive cancer care products in the region over the next few years. The Europe market is expected to expand at a stable CAGR over the forecast period. Major companies based in Europe are looking to expand their base outside Europe to better cater to growing global demand for cancer supportive care products.

Brazil is expected to contribute the largest market share in the Latin America cancer supportive care product market and is expected to witness stable growth in terms of market value during the forecast period. However, late diagnosis of cancer that leads to epidemiological transition, wherein the cancer shifts from being an infectious disease to a chronic disease, is a factor expected to restrict the growth of the overall cancer supportive care products market in Latin America.       

Globally, the Asia-Pacific market is expected to expand at the highest CAGR, followed by North America, Europe, and Latin America. The Middle East & Africa accounts for a nominal share of the overall cancer supportive care products market currently but is expected to evolve over time with the expansion of infrastructural healthcare facilities and skill base of pharmacists in the region.

Key market participants covered in the report include Amgen Inc., Johnson & Johnson, Novartis Ag., Baxter International Inc, Fagron Group BV, Teva Pharmaceuticals Industries Ltd, Hoffmann LA- Roche Ltd, APR Applied Pharma Science Research S.A., Acacia Pharma Ltd, and Kyowa Hakko Kirin Co Ltd.

cancer-supportive-care-products-market

Key market participants covered in the report:

  • Amgen Inc.
  • Johnson & Johnson.
  • Novartis Ag.
  • Baxter International Inc.
  • Fagron Group BV.
  • Teva Pharmaceuticals Industries Ltd.
  • Hoffmann LA- Roche Inc.
  • APR Applied Pharma Science Research S.A.
  • Acacia Pharma Ltd.
  • Kyowa Hakko Kirin Co Ltd.
  • Other.
Back To Top